US5843442A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Blood coagulation protein antagonists and uses therefor
Assignee: Dendreon Pharmaceuticals LLC
•
Filing: 1995-05-30
•
Granted: 1998-12-01
•
Expires: 2015-05-30
Abstract
Abstract Coagulation protein antagonists are disclosed, which include monoclonal-type antibodies and related cell lines disclosed for the production of specific, neutralizing antibodies against factors VII and VIIa and the tissue factor/factor VIIa bimolecular complex, which antibodies are useful for the prevention or treatment of thrombotic and related diseases, for immunoaffinity isolation and purification of factors VII and VIIa and the tissue factor/factor VIIa complex, and for determination of factors VII or VIIa and the tissue factor/factors VII or VIIa complex in a biological sample.
Inventors
- 👤 Howard R. Soule
- 👤 Terence K. Brunck
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 12:14
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/40; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
137 words
A method of treating a mammalian species for a thrombotic disease condition that would be inhibited by an agent that selectively interferes with the coagulation cascade, which comprises administering to a mammalian species in need of such treatment a therapeutically effective amount of an agent selected from the group consisting of: (i) monoclonal-antibody 12D10 produced by hybridoma cell line ATTC HB 10558: (ii) monoclonal antibody active at the epitope bound by monoclonal antibody 12D10 that is a tissue factor:factor VII and/or tissue factor:factor VIIa complex antagonist, (iii) an epitope binding fragment of monoclonal antibody 12D10, and (iv) a functional fragment of a monoclonal antibody active at the epitope bound by monoclonal antibody 12D10 wherein said functional fragment specifically binds with said complex but does not compromise hemostasis by inhibiting free factor VII from binding to tissue factor.
Claim 2
Independent Claim
137 words
A method of treating a mammalian species for a thrombotic disease condition that would be inhibited by an agent that selectively interferes with the coagulation cascade, which comprises administering to a mammalian species in need of such treatment a therapeutically effective amount of an agent selected from the group consisting of: (i) monoclonal-antibody 12D10 produced by hybridoma cell line ATTC HB 10558: (ii) monoclonal antibody active at the epitope bound by monoclonal antibody 12D10 that is a tissue factor:factor VII and/or tissue factor:factor VIIa complex antagonist, (iii) an epitope binding fragment of monoclonal antibody 12D10, and (iv) a functional fragment of a monoclonal antibody active at the epitope bound by monoclonal antibody 12D10 wherein said functional fragment specifically binds with said complex but does not compromise hemostasis by inhibiting free factor VII from binding to tissue factor.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein said thrombotic disease condition is acute disseminated intravascular coagulation.
Claim 4
Dependent Claim
13 words
The method of claim 1 wherein said thrombotic disease condition is septic shock.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein said thrombotic disease condition is coronary thrombosis.
Claim 6
Dependent Claim
14 words
The method of claim 1 wherein said thrombotic disease condition is organ transplant rejection.
Claim 7
Dependent Claim
14 words
The method of claim 1 wherein said thrombotic disease condition is deep vein thrombosis.
Claim 8
Dependent Claim
28 words
The method of claim 1 wherein said agent has the ability to substantially inhibit the procoagulant activity of the tissue factor:factor VII/VIIa complex following formation of the complex.
Claim 9
Dependent Claim
14 words
The method of claim 7 wherein said agent binds free factor VII or VIIa.
Claim 10
Dependent Claim
25 words
The method of claim 7 wherein said agent has the in vitro coagulation antagonist characteristics of antibodies produced by hybridoma cell line ATTC HB 10558.
Claim 11
Dependent Claim
20 words
The method of claim 9 wherein said agent is monoclonal antibody 12D10 produced by hybridoma cell line ATTC HB 10558.
Claim 12
Independent Claim
27 words
The method of any of claims 1-8 or 9 wherein said agent is a F(ab) fragment of monoclonal-antibody 12D10 produced by hybridoma cell line ATTC HB 10558.
Claim 13
Dependent Claim
13 words
The method of claim 1 wherein said agent is a monoclonal antibody fragment.
Claim 14
Dependent Claim
15 words
The method of claim 12 wherein said monoclonal antibody fragment is an F v fragment.
Claim 15
Dependent Claim
38 words
The method of claim 1 wherein said agent comprises a monoclonal antibody preparation, said monoclonal antibody having the ability to complex with a loop region on the factor VII/VIIa molecule, wherein said loop region comprises amino acids 195-208.
Claim 16
Independent Claim
123 words
A method of inhibiting the procoagulant activity of the tissue factor:factor VIIa complex in vivo which comprises administering to a mammalian species a therapeutically effective amount of an agent selected from the group consisting of: (i) monoclonal antibody 12D10 produced by hybridoma cell line ATTC HB 10558, (ii) monoclonal antibody active at the epitope bound by monoclonal antibody 12D10, (iii) a epitope binding fragment of monoclonal antibody 12D10, and (iv) a functional fragment of a monoclonal antibody active at the epitope bound by monoclonal antibody 12D10 wherein said functional fragment specifically binds with said complex but does not compromise hemostasis by inhibiting free factor VII from binding to tissue factor and thereby inhibiting procoagulant activity following conversion of factor VII to factor VIIa.
Claim 17
Independent Claim
123 words
A method of inhibiting the procoagulant activity of the tissue factor:factor VIIa complex in vivo which comprises administering to a mammalian species a therapeutically effective amount of an agent selected from the group consisting of: (i) monoclonal antibody 12D10 produced by hybridoma cell line ATTC HB 10558, (ii) monoclonal antibody active at the epitope bound by monoclonal antibody 12D10, (iii) a epitope binding fragment of monoclonal antibody 12D10, and (iv) a functional fragment of a monoclonal antibody active at the epitope bound by monoclonal antibody 12D10 wherein said functional fragment specifically binds with said complex but does not compromise hemostasis by inhibiting free factor VII from binding to tissue factor and thereby inhibiting procoagulant activity following conversion of factor VII to factor VIIa.
Claim 18
Dependent Claim
21 words
The method of claim 15 wherein said agent binds to free factor VII or factor VIIa and thereby inhibits procoagulant activity.
Claim 19
Dependent Claim
12 words
The method of claim 15 wherein said agent is monoclonal antibody 12D10.
Claim 20
Dependent Claim
24 words
The method of claim 15 wherein said agent is an F(Ab) fragment of monoclonal antibody 12D10 produced by hybridoma cell line ATTC HB 10558.
References Cited (Backward Citations)
US4382083A
Cited
WO1989012463A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-11-30 | 2002-06-01 | 2002-12-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-11-30 | 2006-06-01 | 2006-12-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-11-30 | 2010-06-01 | 2010-12-01 | $7700.00 | Window Closed / Lapsed |